Literature DB >> 29066517

Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder.

Maria Livia Fantini1,2,3, Michela Figorilli2,4, Isabelle Arnulf5, Maurizio Zibetti6, Bruno Pereira7, Patricia Beudin1, Monica Puligheddu4, Florence Cormier-Dequaire8, Lucette Lacomblez8, Eve Benchetrit8, Jean Christophe Corvol8, Alessandro Cicolin9, Leonardo Lopiano6, Ana Marques2,3, Franck Durif2,3.   

Abstract

INTRODUCTION: Because the association between rapid eye movement sleep behaviour disorder (RBD) and impulse control disorders (ICDs) in Parkinson's disease (PD) has been debated, we assessed the sleep characteristics and the frequency of RBD using video-polysomnography (v-PSG) in patients with PD with versus without ICDs.
METHODS: Eighty non-demented patients with PD consecutively identified during routine evaluation at three movement disorders centres were enrolled in a case-control study. Forty patients (22 men; mean age: 62.6±9.7 years, Hoehn & Yahr: 2.1±0.6) with one or more current ICDs were age-matched and sex-matched with 40 patients with no history of ICDs (22 men, mean age: 64.9±7.8 years, Hoehn & Yahr: 2.2±0.6). They underwent a detailed sleep interview followed by a full-night in-lab v-PSG. Sleep was scored blindly to ICDs condition and RBD diagnosis included a clinical complaint of enacted dreams and/or documented behaviour during rapid eye movement (REM) sleep, with the presence of quantified REM sleep without atonia (RSWA).
RESULTS: Patients with ICDs had a higher arousal index and higher RSWA than those without ICDs (51.9%±28.2%vs 32.2±27.1%, p=0.004). In addition, RBD was more frequent in the ICD group (85%vs53%, p=0.0001). RBD was still associated with ICDs in a multivariate regression analysis including age of onset, PD duration and severity, treatment duration, levodopa-equivalent and dopamine agonist-equivalent daily doses and antidepressant use (OR: 4.9 (95% CI 1.3 to 18.5), p=0.02).
CONCLUSIONS: This large, controlled series of patients with PD with ICDs assessed by v-PSG confirms the association between ICDs and RBD. Increased surveillance of symptoms of ICDs should be recommended in patients with PD with RBD. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29066517     DOI: 10.1136/jnnp-2017-316576

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  5 in total

Review 1.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  Anna Nagy; Anette Schrag
Journal:  J Neural Transm (Vienna)       Date:  2019-05-29       Impact factor: 3.575

Review 2.  Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease.

Authors:  Robert S Eisinger; Adolfo Ramirez-Zamora; Samuel Carbunaru; Brandon Ptak; Zhongxing Peng-Chen; Michael S Okun; Aysegul Gunduz
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003

3.  Impulse control disorders in Parkinson disease and RBD: A longitudinal study of severity.

Authors:  Fahd Baig; Mark J Kelly; Michael A Lawton; Claudio Ruffmann; Michal Rolinski; Johannes C Klein; Thomas Barber; Christine Lo; Yoav Ben-Shlomo; David Okai; Michele T Hu
Journal:  Neurology       Date:  2019-07-16       Impact factor: 9.910

4.  Progressive Prefrontal Cortex Dysfunction in Parkinson's Disease With Probable REM Sleep Behavior Disorder: A 3-Year Longitudinal Study.

Authors:  Xiuqin Jia; Wentao Fan; Zhijiang Wang; Yuehong Liu; Ying Li; Haibin Li; Hui Li; Ting Ma; Jing Wang; Qi Yang
Journal:  Front Aging Neurosci       Date:  2022-01-10       Impact factor: 5.750

5.  Genetic prediction of impulse control disorders in Parkinson's disease.

Authors:  Daniel Weintraub; Marijan Posavi; Pierre Fontanillas; Thomas F Tropea; Eugenia Mamikonyan; Eunran Suh; John Q Trojanowski; Paul Cannon; Vivianna M Van Deerlin; Alice S Chen-Plotkin
Journal:  Ann Clin Transl Neurol       Date:  2022-06-27       Impact factor: 5.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.